Reviewed by Michael Gill, B. Sc.
25 Glaucoma Clinical Trials Near Me
Top Hospitals for Glaucoma Clinical Trials
Image of Eye Research Foundation in California.
Eye Research Foundation
Newport Beach
5Active Trials
17All Time Trials for Glaucoma
2007First Glaucoma Trial
Image of Duke Eye Center in North Carolina.
Duke Eye Center
Durham
4Active Trials
12All Time Trials for Glaucoma
2013First Glaucoma Trial
Top Cities for Glaucoma Clinical Trials
Glaucoma Clinical Trials by Phase of Trial
Phase < 1 Glaucoma Clinical Trials
1Active Glaucoma Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Yutiq 0.18 MG Drug Implant
Glaucoma Clinical Trials by Age Group
18+ Glaucoma Clinical Trials
84Active Glaucoma Clinical Trials
Active SASmNGENUITYCorNeat EverPatchBimatoprost OphthalmicKinezodianone R hydrochlorideOcular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)Fixed force GATIn-House Developed VR Platform - AMD, DR, Glaucoma
Most Recent Glaucoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Glaucoma Clinical Trials
Treatment Name
Active Glaucoma Clinical Trials
All Time Trials for Glaucoma
First Recorded Glaucoma Trial
Active SASm
2
2
2023
CorNeat EverPatch
2
2
2020
Test - Bimatoprost 0.01% Ophthalmic Solution
2
2
2021
Bimatoprost SR
2
6
2014
DE-117 Ophthalmic Solution
2
3
2018
Recently Completed Studies with FDA Approved Treatments for Glaucoma
Treatment
Year
Sponsor
QLS-101ophthalmic solution 2%
2021
Qlaris Bio, Inc.
QLS-101
2021
Qlaris Bio, Inc.
Brinzolamide/brimonidine ophthalmic suspension
2021
Perrigo Company
Timolol Ophthalmic Suspension 0.5 Percent
2021
Betaliq, Inc.
QLS-101
2021
Qlaris Bio, Inc.
DE-126 Ophthalmic Solution 0.002% QD
2020
Santen Inc.
NCX 470 0.065%
2020
Nicox Ophthalmics, Inc.
ST266 via Intranasal Delivery
2019
Noveome Biotherapeutics, formerly Stemnion

What Are Glaucoma Clinical Trials?

According to Mayo Clinic, Glaucoma is identified as a series of eye conditions that damage the optic nerve. Glaucoma is not age specific but is more commonly identified in older adults and is the main cause of blindness in those over 60.

Glaucoma clinical trials are being conducted worldwide to improve the diagnosis of glaucoma and managing and treating this condition. In addition, clinical trials for glaucoma aim to help find new treatments for glaucoma and can increase the quality of life of those suffering from glaucoma.

Why Is Glaucoma Being Studied Through Clinical Trials?

Glaucoma is being studied through clinical trials to identify those most at risk of developing glaucoma. Clinical trials also help those most likely to benefit from early treatment of this condition. Clinical trials focused on glaucoma also help identify new treatments for those already diagnosed.

The National Library Of Medicine indicates that there are 57.5 million people around the world affected by glaucoma, and this number is expected to increase to 111.8 million by 2040. A combination of factors contributes to being diagnosed with glaucoma, and it is the leading cause of blindness after cataracts.

What Are The Types Of Treatments Available For Glaucoma?

Glaucoma is treated by a number of treatments, including prescription eye drops, surgery, oral medicine, and laser therapy.

Glaucoma treatment often starts with prescription eye drops. If eye drops are not effective in glaucoma management, prescription oral medication may be recommended.

What Are Some Recent Breakthrough Clinical Trials For Glaucoma?

There have been a few studies that show promising results in treating glaucoma. Some of the most impressive clinical trials include:

2017: New medication to treat glaucoma – This clinical trial focuses on combining IOP-lowering medications with treatments that protect the retinal ganglion cells. David Krizaj, a vision scientist, has been researching how cells communicate with one another and is working to identify why the pressure-sensing mechanism in the eye causes damage in the case of glaucoma.

2021: Injection to treat glaucoma – Scientists may have discovered an injection developed through gene editing as a treatment for glaucoma. This clinical trial aims to treat glaucoma by injecting the protein Hepta-ANGPT1, which replaces the mutated genes which cause glaucoma.

2022: Nicotinamide for the treatment of Glaucoma – Nicotinamide is currently being tested to treat glaucoma. This form of vitamin B3 protects glaucoma patients from experiencing more vision loss. This clinical trial will also investigate biomarkers that can predict the progression of glaucoma in patients.

Who Are Some Of The Key Opinion Leaders / Researchers In Glaucoma Clinical Trials?

Professor Keith Martin is the managing director at CERA. His primary focus is on glaucoma, and his research is based on finding new ways to protect and regenerate the optic nerve. The CERA researchers are also studying the potential benefits vitamin B3 has in helping patients with glaucoma.

George A Cioffi, MD, specializes in cataract surgery, glaucoma, and ophthalmology and is a recognized glaucoma scientist. He is an author of more than 200 articles and has received numerous awards in his field of research.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: November 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, Burton D, Wormald R, Evans JR. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022 Aug 9;8:CD003919. doi: 10.1002/14651858.CD003919.pub3. Review. https://pubmed.ncbi.nlm.nih.gov/359431142 Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7. https://pubmed.ncbi.nlm.nih.gov/164889403 Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database Syst Rev. 2017 Jul 3;7:CD010516. doi: 10.1002/14651858.CD010516.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/286707104 Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr Opin Ophthalmol. 2011 Mar;22(2):133-6. doi: 10.1097/ICU.0b013e328343723d. Review. https://pubmed.ncbi.nlm.nih.gov/211912925 Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012 Mar;23(2):96-104. doi: 10.1097/ICU.0b013e32834ff1e7. Review. https://pubmed.ncbi.nlm.nih.gov/222492336 Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067. https://pubmed.ncbi.nlm.nih.gov/245311207 Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012 Mar;23(2):96-104. doi: 10.1097/ICU.0b013e32834ff1e7. Review. https://pubmed.ncbi.nlm.nih.gov/222492338 Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009 Apr;116(4):640-51. doi: 10.1016/j.ophtha.2008.12.058. Epub 2009 Feb 25. https://pubmed.ncbi.nlm.nih.gov/192438309 Waisbourd M, Shafa A, Delvadia R, Sembhi H, Molineaux J, Henderer J, Pizzi LT, Myers JS, Hark LA, Katz LJ. Bilateral Same-day Laser Peripheral Iridotomy in the Philadelphia Glaucoma Detection and Treatment Project. J Glaucoma. 2016 Oct;25(10):e821-e825. doi: 10.1097/IJG.0000000000000409. https://pubmed.ncbi.nlm.nih.gov/2695057910 Wang Q, Harissi-Dagher M. Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience. Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28. https://pubmed.ncbi.nlm.nih.gov/25174898